Loading clinical trials...

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme | Clinical Trials | Clareo Health

UNKNOWNPHASE2/PHASE3

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study

NCT03025893•Amsterdam UMC, location VUmc

View on ClinicalTrials.gov

Summary

In this study the investigators will evaluate the effect of high-dose, intermittent sunitinib versus treatment with lomustine in patients with recurrent glioblastoma multiforme. The investigators hypothesize that sunitinib, when given in a high-dose, intermittent schedule, will achieve adequate concentration levels in the tumor and will, besides its anti-angiogenic properties, inhibit gliomagenesis by inhibition of multiple kinases.

Detailed Description

Study design: Multicenter, phase II/III, randomized clinical trial with high-dose sunitinib versus lomustine (CCNU) in patients with recurrent GBM. Hypothesis: Sunitinib, when given in a high-dose, intermittent schedule, may exhibit improved efficacy in patients with recurrent GBM with an acceptable toxicity profile, compared to lomustine. Study population: Adult patients with recurrent GBM. Primary objective: \- To determine the effect of high-dose sunitinib versus lomustine on six-month progression-free survival (PFS6) in patients with recurrent GBM, using the RANO criteria. Secondary objectives: * To determine the effect of high-dose sunitinib on overall survival (OS 9, OS 12) in patients with recurrent GBM. * To assess the objective radiological response rate, using the RANO criteria. * To assess toxicity, using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0. * To assess patient-oriented criteria: steroid use and health-related quality of life (reported by patients and caregivers/relatives). * To explore the potential value of blood markers for molecular diagnostics, disease and response monitoring. * To explore if MGMT promoter methylation status modulates the response to sunitinib. Treatment: After randomization, 100 patients will be divided equally over two treatment groups and will receive: * Group 1 (experimental arm): Sunitinib, 700 mg administered orally every 2 weeks. * Group 2 (control arm): Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks. Disease will be assessed by MRI according to an uniform neuro-oncology protocol every 6 weeks for the first 6 months and every 12 weeks until documented progression. Safety profile of both treatment strategies will be assessed separately for each cycle of therapy and every 12 weeks after the end of treatment if adverse effects have not resolved or are newly emerging. Furthermore, quality of life assessment takes place every 6 weeks using questionnaires.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed (by the patient or legally acceptable representative) and dated Informed Consent Form
•2. Histologically confirmed de novo or secondary glioblastoma with unequivocal first progression, at least 3 months off radiotherapy.
•3. No more than one line of chemotherapy (concurrent and adjuvant temozolomide based chemotherapy including in combination with another investigational agent is considered one line of chemotherapy). Chemotherapy must have been completed at least 4 weeks prior to randomization.
•4. Patients may have undergone surgery for recurrence. If operated, residual and measurable disease after surgery is not required but surgery must have confirmed the recurrence.
•5. No radiotherapy, stereotactic radiosurgery or brachytherapy as treatment for recurrence.
•6. Patients must have a Karnofsky Performance Score ≥ 70%
•7. Patients need to have adequate hematological, renal and hepatic function as assessed by the following laboratory requirements to be conducted within seven days prior to start study treatment:
•1. Hemoglobin ≥ 7.0 mmol/L
•2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
•3. Platelet count ≥ 100 x 109/L
+4 more criteria

Exclusion Criteria

•1. Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture.
•2. Patients with a prior (\< 5 years) or concomitant second malignancy.
•3. Prior radiotherapy in the abdomen or in the lungs or in more than 3 vertebrae in the spine (Less than 3 vertebrae are considered a small radiation field and eligibility will be decided on an individual basis from the PI).
•4. Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be ≤ 160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements.
•5. Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds.)
•6. Initial MR-scan of the brain showing intratumoral hemorrhage, except for stable post-operative grade 1 hemorrhage.
•7. Known hypersensitivity to sunitinib or to its excipients.
•8. Presence of any significant central nervous system or psychiatric disorder(s) that would interfere with the patient's compliance.
•9. Use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic (as opposed to prophylactic) purposes.
•10. Use of strong hepatic enzyme-inducing antiepileptic drugs, such as carbamazepine, phenobarbital and phenytoin. If a patient uses one or more of these specific antiepileptic drugs, they must switch to an antiepileptic drug that does not interact with cytochrome P450 (CYP450) liver enzymes, such as levetiracetam, prior to the start of study treatment.
+5 more criteria

Locations (3)

VU University Medical Center

Amsterdam, Netherlands

University Medical Center Groningen

Groningen, Netherlands

Radboud UMC

Nijmegen, Netherlands

Key Dates

Start Date

August 31, 2018

Primary Completion Date

January 1, 2022

Completion Date

January 1, 2022

Last Updated

April 19, 2021

Enrollment

100

ESTIMATED participants

Conditions

Glioblastoma MultiformeGlioblastoma, AdultGlioblastomaRecurrent Brain TumorGBM

Interventions

Sunitinib

DRUG

Lomustine

DRUG

Contacts

Myra E Van Linde, MD

CONTACT

+31 20 444 4321 trialoffice-onc@vumc.nl

Jorien Janssen, MD

CONTACT

jorien.janssen@radboudumc.nl; trialoffice-onc@vumc.nl

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

NCT00083512

Glioblastoma Multiforme

View study

RECRUITING

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 19, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

Inclusion Criteria

Exclusion Criteria

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Targeted Pediatric High-Grade Glioma Therapy

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma